A cost-effectiveness analysis of a new and more effective treatment for unresectable hepatocellular carcinoma—from a Chinese perspective
Under the threshold of three times China's per capita GDP, anlotinib plus penpulimab is more cost-effective compared with sorafenib.
Authors
- B. Shou
- Zuojun Dong
- Li Huang (ORCID: https://orcid.org/0000-0003-1432-2054)
- Zhenyu Huang (ORCID: https://orcid.org/0000-0002-4502-0086)
- Jianhua Chen (ORCID: https://orcid.org/0000-0002-7293-0333)
- Guojun Sun
Institutions
- Zhejiang University of Technology (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2025-12-07
- DOI
- https://doi.org/10.1080/07853890.2025.2598903
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00